{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for vitamin root_notes_note in Note (approximate match)
Status:
Possibly Marketed Outside US
Source:
21 CFR 333A
(2016)
Source URL:
First approved in 2016
Source:
21 CFR 333A
Source URL:
Class:
MIXTURE
Status:
Possibly Marketed Outside US
Source:
NCT03538327: Phase 4 Interventional Completed Hypertension
(2013)
Source URL:
First approved in 2016
Source:
21 CFR 352
Source URL:
Class:
MIXTURE
Status:
Possibly Marketed Outside US
Source:
21 CFR 333A
(2020)
Source URL:
First approved in 2016
Source:
21 CFR 347
Source URL:
Class:
MIXTURE
Status:
Possibly Marketed Outside US
First approved in 2015
Source:
NADA141438
Source URL:
Class:
MIXTURE
Targets:
Conditions:
Avilamycin is an orthosomycin antibiotic complex produced by the fermentation of Streptomyces viridochromogenes. Avilamycin is intended for use as a veterinary medicine in chickens, turkeys, pigs and rabbits to control bacterial enteric infections. It exhibits good antimicrobial activity against important veterinary Gram-positive pathogens (e.g., Clostridium perfringens) and has no related molecules in its class in human use. Therefore, avilamycin has been developed for treating necrotic enteritis in poultry, and enteric disease in pig and rabbits. Avilamycin inhibits bacterial protein synthesis through a novel mechanism of action by binding to the 50S ribosomal subunit and preventing the association of IF2, which inhibits the formation of the mature 70S initiation complex, and the correct positioning of tRNA in the aminoacyl site. No adverse drug-related changes were observed.
Status:
Possibly Marketed Outside US
Source:
21 CFR 358H
(2019)
Source URL:
First approved in 2014
Source:
M006
Source URL:
Class:
MIXTURE
Status:
Possibly Marketed Outside US
Source:
21 CFR 348
(2014)
Source URL:
First approved in 2014
Source:
21 CFR 348
Source URL:
Class:
MIXTURE
Status:
Possibly Marketed Outside US
Source:
21 CFR 333A
(2014)
Source URL:
First approved in 2014
Source:
21 CFR 333A
Source URL:
Class:
MIXTURE
Status:
Possibly Marketed Outside US
Source:
21 CFR 352
(2012)
Source URL:
First approved in 2012
Source:
21 CFR 352
Source URL:
Class:
MIXTURE
Status:
Possibly Marketed Outside US
Source:
NCT04160767: Phase 4 Interventional Unknown status Celiac Disease
(2019)
Source URL:
First approved in 2010
Source:
21 CFR 352
Source URL:
Class:
MIXTURE
Status:
Possibly Marketed Outside US
First approved in 2009
Source:
Bambermycin Concentrate by Biovet Joint Stock Company
Source URL:
Class:
MIXTURE
Targets:
Conditions:
Bambermycins (flavomycin) is a complex of antibiotics obtained from Streptomyces bambergiensis and Streptomyces ghanaensis used as a food additive for poultry and swine. Inhibitor of the in vitro transglycosylase activities of PBPs. Bambermycins complex consists mainly of moenomycins A and C. Moenomycin A is the prototype for compounds that bind to bacterial peptidoglycan glycosyltransferases (PGTs) and inhibit cell wall biosynthesis